Clinical Trials
22 trialsNCT07296666 2025-12-22
Adjuvant Chemotherapy for BTC Based on 3D-PTA
Fudan University
Phase 2 Not yet recruiting
NCT06406816 2025-05-15
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase EARLY_PHASE1 Recruiting
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT02170090 2025-03-30
ACTICCA-1
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Active not recruiting
NCT06037980 2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3 Recruiting
NCT06607276 2025-01-16
ACHIEVE
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04295317 2025-01-03
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
Shanghai Zhongshan Hospital
Phase 2 Active not recruiting
NCT03079427 2022-12-06
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Asan Medical Center
Phase 2 Completed
NCT04782804 2022-08-18
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Fudan University
Phase 1/2 Unknown
NCT04856761 2022-08-18
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Fudan University
Unknown
NCT01247337 2020-10-05
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
Herlev Hospital
Phase 2 Completed
NCT00779454 2020-02-06
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
Vejle Hospital
Phase 2 Completed
NCT03779035 2018-12-19
AdBTC-1
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03117855 2017-04-18
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
City of Hope Medical Center
Phase 1 Withdrawn
NCT01007552 2017-03-29
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Roswell Park Cancer Institute
Phase 2 Completed
NCT01206049 2017-03-13
GOC-B-P
Vejle Hospital
Phase 2 Completed
NCT01572324 2017-01-04
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase 2 Completed
NCT01151761 2016-07-29
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
Phase 2 Terminated
NCT02798510 2016-06-22
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
Fudan University
Phase 3 Unknown
NCT02548195 2015-09-14
Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 3 Unknown
NCT00630890 2015-09-11
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
University of California, San Francisco
Phase 1 Terminated
NCT00350961 2008-08-26
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
Rigshospitalet, Denmark
Phase 1/2 Completed